The project is based on capillary electrophoresis coupled to mass spectrometry (CE-MS). CE-MS analysis of urinary peptides is reproducible, robust, operator-independent, precise (including inter-laboratory precision) and stable (1). Results from a multicentre prospective study confirmed that peptide detection using CE-MS is insensitive to sample collection, handling, and storage in different centres (1). The method was found to be acceptable by the regulatory agencies European Medicines Agency (EMA) and US Food and Drug Administration (FDA). In the context of early detection of CKD, the approach has received a “Letter of Support from the FDA (2).